• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

New research connects visual health and depression

Article

This research collaboration between Chinese and Australian researchers set out to investigate the connection in the UK Biobank Study cohort.

New research discovers a tie between visual health, depressive symptoms, and altered brain neurobiology.1

This research collaboration between Chinese and Australian researchers set out to investigate the connection in the UK Biobank Study cohort. In this study, conducted from March to June 2006 to July 2010 that included 114,583 volunteers (54.5% women; mean participant age, 56.8 years; range, 39-72 years), the investigators studied the association between depression and brain micro- and macrostructure in subgroups divided by visual acuity (VA).

Vision loss and depression are common conditions with major health implications, explained Xiayin Zhang, PhD, from the Guangdong Eye Institute, Department of Ophthalmology, and the Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. However, the mechanism of that association remains to be clarified.

The habitual distance VA was measured using the logarithm of the minimum angle of resolution (logMAR) characters. Depression was identified based on the Patient Health Questionnaire (PHQ) or through an interview-based psychiatric diagnosis. Subgroup participants underwent multimodal magnetic resonance imaging (MRI) of the brain and PHQ evaluation during the imaging visit after 2014.

The main outcomes and measures were depression, depressive symptoms, and imaging-derived phenotypes from T1-weighted and diffusion MRI.

Depression and vision association

The results indicated that a 1-line worse VA (0.1 logMAR increase) was associated with a 5% higher odds of depression (odds ratio, 1.05; 95% confidence interval [CI], 1.04-1.07) after adjustment for age; sex race; ethnicity; Townsend index; educational qualifications; smoking; alcohol consumption; obesity; physical activity; history of hypertension, diabetes, and hyperlipidemia; and family history of depression.

The investigators reported that of the 7,844 participants who underwent MRI, “a linear association was seen between the PHQ score and the left volume of gray matter in the supracalcarine cortex (coefficient, 7.61; 95% CI, 3.90-11.31) and the mean isotropic volume fraction (ISOVF) in the right fornix (cres) and/or stria terminalis (coefficient, 0.003; 95% CI, 0.001-0.004) after correction for multiple comparison. In addition, their association could be moderated by VA, whereby an increased PHQ score was associated with higher ISOVF levels only among those with poorer VA (p = 0.02 for interaction).”

The results suggested an association between visual health and depression and that the diffusion characteristic of ISOVF in the fornix (cres) and/or stria terminalis is associated with depressive symptoms in participants with poorer VA.

Zhang advised that health care providers consider these outcomes when performing routine mental health screening.

Reference
1. Zhang X, Shang X, Seth I, et al. Association of visual health with depressive symptoms and brain imaging phenotypes among middle-aged and older adults. JAMA Netw Open. 2022;5(10):e2235017. doi:10.1001/jamanetworkopen.2022.35017
Related Videos
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
Kelsey Roelofs, MD, details the best methods to identify thyroid eye disease at CIME 2024
David A. Berntsen, OD, PhD, FAAO, outlines his presentation on the BLINK 2 study presented at the 2024 ARVO meeting
© 2024 MJH Life Sciences

All rights reserved.